1362 related articles for article (PubMed ID: 32029455)
1. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
3. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
[TBL] [Abstract][Full Text] [Related]
4. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
Gravells P; Grant E; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
[TBL] [Abstract][Full Text] [Related]
5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
6. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
Pillay N; Brady RM; Dey M; Morgan RD; Taylor SS
Prog Biophys Mol Biol; 2021 Aug; 163():160-170. PubMed ID: 33524442
[TBL] [Abstract][Full Text] [Related]
7. PARG Inhibitors and Functional PARG Inhibition Models.
Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
[TBL] [Abstract][Full Text] [Related]
8. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
Harrision D; Gravells P; Thompson R; Bryant HE
Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Masutani M; Nakagama H; Sugimura T
Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
[TBL] [Abstract][Full Text] [Related]
11. PARP and PARG inhibitors--new therapeutic targets in cancer treatment.
Fauzee NJ; Pan J; Wang YL
Pathol Oncol Res; 2010 Dec; 16(4):469-78. PubMed ID: 20383759
[TBL] [Abstract][Full Text] [Related]
12. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
14. Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei.
Schlesinger M; Vilchez Larrea SC; Haikarainen T; Narwal M; Venkannagari H; Flawiá MM; Lehtiö L; Fernández Villamil SH
Parasit Vectors; 2016 Mar; 9():173. PubMed ID: 27007296
[TBL] [Abstract][Full Text] [Related]
15. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis.
Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ
Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
18. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
19. A review on mechanisms of resistance to PARP inhibitors.
Desai C; Pathak A; Limaye S; Maniar V; Joshi A
Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
[TBL] [Abstract][Full Text] [Related]
20. Mitotic functions of poly(ADP-ribose) polymerases.
Slade D
Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
